AcelRx presents results of SAP302 study of ARX-04

AcelRx Pharmaceuticals has presented the results from its Phase 3 SAP302 study of ARX-04 by representatives from the company and its investigators.
During the SAP302 study, 76 patients were treated in the emergency department with ARX-04 for moderate-to-severe acute pain. The results were presented at the International Society for Burn Injuries in Miami, and included any injuries that were sustained by patients during the study.
The mean pain intensity difference in the study was 2.9 from a baseline of 8.1, which was rated every 60 minutes on a numeric scale of 0-10, which met the primary goal of SAP302. The various types of injuries that patients suffered during the study included fractures, sprains/strains, lacerations and burns.
ARX-04 was received well by the patients, with only 9 percent experiencing nausea, 5 percent experiencing somnolence and 4 percent experiencing vomiting. It was also determined that ARX-04 had no impact of cognitive functions.